Lexicon Pharmaceuticals

Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. A Diverse Pipeline of Targeted Therapies Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
Company Growth (employees)
Type
Public
HQ
Spring, US
Founded
1995
Size (employees)
168 (est)+40%
Lexicon Pharmaceuticals was founded in 1995 and is headquartered in Spring, US

Key People at Lexicon Pharmaceuticals

Raymond Debbane

Raymond Debbane

Chairman of the Board
Pablo Lapuerta

Pablo Lapuerta

Executive Vice President of Clinical Development and Chief Medical Officer
Jeffrey L. Wade

Jeffrey L. Wade

Executive Vice President and Chief Financial Officer
Alan J. Main

Alan J. Main

Executive Vice President of Pharmaceutical Research
James F. Tessmer

James F. Tessmer

Vice President of Finance and Accounting

Lexicon Pharmaceuticals Office Locations

Lexicon Pharmaceuticals has offices in Spring, The Woodlands, Boston, Philadelphia and in 27 other locations
Spring, US (HQ)
8800 Technology Forest Place

Lexicon Pharmaceuticals Data and Metrics

Lexicon Pharmaceuticals Financial Metrics

Lexicon Pharmaceuticals's revenue was reported to be $83.3 m in FY, 2016 which is a 36% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

83.3 m

Revenue growth (FY, 2015 - FY, 2016), %

(36%)

Net income (FY, 2016)

(141.4 m)

EBIT (FY, 2016)

(137.2 m)

Market capitalization (26-May-2017)

1.5 b

Closing share price (26-May-2017)

14.6

Cash (31-Dec-2015)

203 m

EV

1.4 b
Lexicon Pharmaceuticals's current market capitalization is $1.5 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.2 m22.9 m130 m83.3 m

Revenue growth, %

929%469%(36%)

Operating expense total

104.6 m123.2 m128.5 m220.5 m

EBIT

(102.4 m)(100.4 m)1.5 m(137.2 m)

EBIT margin, %

(4607%)(439%)1%(165%)

Interest expense

2 m2.3 m6.7 m6.6 m

Interest income

157 k2.3 m572 k2.3 m

Pre tax profit

(104.1 m)(100.4 m)(4.7 m)(141.4 m)

Net Income

(104.1 m)(100.3 m)(4.7 m)(141.4 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Cash

37.5 m137.3 m203 m

Current Assets

134.6 m369 m532.4 m

Goodwill

44.5 m44.5 m44.5 m

Total Assets

274.2 m471.4 m654.8 m

Accounts Payable

9.7 m13.1 m19.7 m

Total Debt

21.9 m107.7 m105.8 m

Current Liabilities

19.3 m45 m123 m

Additional Paid-in Capital

1.2 b1.4 b1.4 b

Retained Earnings

(1 b)(1.1 b)(1.1 b)

Total Equity

170.2 m284 m285.9 m

Debt to Equity Ratio

0.1 x0.4 x0.4 x

Debt to Assets Ratio

0.1 x0.2 x0.2 x

Financial Leverage

1.6 x1.7 x2.3 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Cash From Operating Activities

(91.1 m)(75.6 m)184.8 m

Purchases of PP&E

(1.7 m)(80 k)(910 k)

Cash From Investing Activities

99.5 m(108.4 m)(117 m)

Cash From Financing Activities

(1.4 m)283.8 m(2 m)

Interest Paid

1.9 m1.8 m6.3 m
Numbers are in $, USDY, 2016

EV/EBIT

-10.4 x

Revenue/Employee

694.5 k

Lexicon Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials

1

Products

1

Phase Preclinical

1

Phase III Trials

2

Lexicon Pharmaceuticals Market Value History

Lexicon Pharmaceuticals Company Life and Culture

You may also be interested in